STOCK TITAN

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Autolus Therapeutics to release Q3 2023 financial results and operational highlights
Positive
  • Autolus Therapeutics plc will release its third quarter 2023 financial results and operational highlights on November 2, 2023.
Negative
  • None.

LONDON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2023 financial results and operational highlights before open of US markets on Thursday, November 2, 2023.

Management will host a conference call and webcast at 9:00 am ET/1:00 pm GMT to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Contact:

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com

Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com

Lauren Williams
Investase
+44 23 9438 7760
lauren@investase.com


FAQ

When will Autolus Therapeutics release its Q3 2023 financial results?

Autolus Therapeutics will release its Q3 2023 financial results on November 2, 2023.

What time is the conference call and webcast?

The conference call and webcast will be held at 9:00 am ET/1:00 pm GMT.

How can I access the conference call?

Conference call participants should pre-register using the provided link to receive the dial-in numbers and a personal PIN.

Will there be a replay of the webcast?

Yes, a simultaneous audio webcast and replay will be accessible on Autolus' website.

Autolus Therapeutics plc American Depositary Share

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Stock Data

1.11B
91.18M
18.04%
53.51%
1.57%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LONDON

About AUTL

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a leading biotechnology company focussed on the development and commercialisation of engineered t-cell therapies for haematological and solid tumours. autolus has the ambition to be a leader of a revolution in medicine in which life-threatening diseases are treated by a patient’s own cells.